Ratanasampil (RNSP) is a traditional Tibetan medicine used for the treatment of stroke and cerebrovascular diseases. Previous discoveries that RNSP can reduce β-amyloid protein levels and increase learning and memory...Ratanasampil (RNSP) is a traditional Tibetan medicine used for the treatment of stroke and cerebrovascular diseases. Previous discoveries that RNSP can reduce β-amyloid protein levels and increase learning and memory in Alzheimer’s mouse models (Tg2576) led us to investigate whether RNSP can improve cognitive functions in Alzheimer’s patients. In this study, 146 AD patients living in Qinghai province received either one gram or 0.33 gram daily of RNSP for 16 weeks. Placebo patients received Piracetam. Serum Aβ40 and Aβ42 levels were measured at the beginning of the study and after 4 and 16 weeks of treatment. Compared to the same group before treatment, MMSE scores, ADAS-cog scores and ADL scores were significantly improved (p 0.05, p > 0.05). After 16-week treatment, serum TNF-α, IL-1β, IL-6 and Aβ42 levels were significantly decreased (p < 0. 01) in the high-dose RNSP group, whereas no significant differences were found in the low-dose and placebo groups. The Aβ42/Aβ40 ratio was significantly decreased after 4-week and 16-week treatment in the high-dose RNSP group (p < 0. 05, p < 0.01). Furthermore, serum Aβ42 concentrations had a strong positive correlation with TNF-α, IL-1β and IL-6 levels. There were no observable adverse effects in either treatment or control groups. We conclude that further clinical trials of RNSP in Alzheimer disease are warranted.展开更多
藏药七十味珍珠丸(Tibetan medicine ratnasampil,RNSP)是预防和治疗阿尔兹海默病(Alzheimer's disease,AD)的前景药物,对防治轻、中度AD具有很好的临床应用价值。RNSP能显著改善轻、中度AD患者的认知功能和日常生活自理能力,具有...藏药七十味珍珠丸(Tibetan medicine ratnasampil,RNSP)是预防和治疗阿尔兹海默病(Alzheimer's disease,AD)的前景药物,对防治轻、中度AD具有很好的临床应用价值。RNSP能显著改善轻、中度AD患者的认知功能和日常生活自理能力,具有改善记忆、修复大脑神经元、提高学习记忆能力、改善大脑氧化应激(oxidative stress,OS)水平等药理作用。RNSP抗AD的机制可能是通过保护神经,降低大脑中和AD相关的β淀粉样蛋白(amyloid,Aβ)水平,抵抗大脑慢性炎症,减少炎症因子激活及抗OS等产生的。建议开展较大规模的多中心随机对照双盲实验,进一步确定RNSP预防和治疗AD的临床价值,并在分子和基因水平加强其药理机制探讨。展开更多
文摘Ratanasampil (RNSP) is a traditional Tibetan medicine used for the treatment of stroke and cerebrovascular diseases. Previous discoveries that RNSP can reduce β-amyloid protein levels and increase learning and memory in Alzheimer’s mouse models (Tg2576) led us to investigate whether RNSP can improve cognitive functions in Alzheimer’s patients. In this study, 146 AD patients living in Qinghai province received either one gram or 0.33 gram daily of RNSP for 16 weeks. Placebo patients received Piracetam. Serum Aβ40 and Aβ42 levels were measured at the beginning of the study and after 4 and 16 weeks of treatment. Compared to the same group before treatment, MMSE scores, ADAS-cog scores and ADL scores were significantly improved (p 0.05, p > 0.05). After 16-week treatment, serum TNF-α, IL-1β, IL-6 and Aβ42 levels were significantly decreased (p < 0. 01) in the high-dose RNSP group, whereas no significant differences were found in the low-dose and placebo groups. The Aβ42/Aβ40 ratio was significantly decreased after 4-week and 16-week treatment in the high-dose RNSP group (p < 0. 05, p < 0.01). Furthermore, serum Aβ42 concentrations had a strong positive correlation with TNF-α, IL-1β and IL-6 levels. There were no observable adverse effects in either treatment or control groups. We conclude that further clinical trials of RNSP in Alzheimer disease are warranted.
文摘藏药七十味珍珠丸(Tibetan medicine ratnasampil,RNSP)是预防和治疗阿尔兹海默病(Alzheimer's disease,AD)的前景药物,对防治轻、中度AD具有很好的临床应用价值。RNSP能显著改善轻、中度AD患者的认知功能和日常生活自理能力,具有改善记忆、修复大脑神经元、提高学习记忆能力、改善大脑氧化应激(oxidative stress,OS)水平等药理作用。RNSP抗AD的机制可能是通过保护神经,降低大脑中和AD相关的β淀粉样蛋白(amyloid,Aβ)水平,抵抗大脑慢性炎症,减少炎症因子激活及抗OS等产生的。建议开展较大规模的多中心随机对照双盲实验,进一步确定RNSP预防和治疗AD的临床价值,并在分子和基因水平加强其药理机制探讨。
